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Background: With recent focus on methicillin-
resistant Staphylococcus aureus (MRSA) screening,
methicillin-susceptible S. aureus (MSSA) has been
overlooked. MSSA infections are costly and debilitating
in orthopaedic surgery.
Methods: We broadened MRSA screening to include
MSSA for elective orthopaedic patients. Preoperative
decolonisation was offered if appropriate. Elective and
trauma patients were audited for staphylococcal
infection during 2 6-month periods (A: January to
June 2013 MRSA screening; B: January to June 2014
MRSA and MSSA screening). Trauma patients are not
screened presurgery and provided a control. MSSA
screening costs of a modelled cohort of 500 elective
patients were offset by changes in number and costs
of MSSA infections to demonstrate the change in total
health service costs.
Findings: Trauma patients showed similar infection
rates during both periods (p=1). In period A, 4
(1.72%) and 15 (6.47%) of 232 elective patients
suffered superficial and deep MSSA infections,
respectively, with 6 superficial (2%) and 1 deep (0.3%)
infection among 307 elective patients during period
B. For any MSSA infection, risk ratios were 0.95 (95%
CI 0.41 to 2.23) for trauma and 0.28 (95% CI 0.12 to
0.65) for elective patients (period B vs period A). For
deep MSSA infections, risk ratios were 0.58 (95% CI
0.20 to 1.67) for trauma and 0.05 (95% CI 0.01 to
0.36) for elective patients (p=0.011). There were 29.12
fewer deep infections in the modelled cohort of 500
patients, with a cost reduction of £831 678 for 500
patients screened.
Conclusions: MSSA screening for elective orthopaedic
patients may reduce the risk of deep postoperative
MSSA infection with associated cost-benefits.
INTRODUCTION
Approximately one in three people are colo-
nised with Staphylococcus aureus (methicillin-
susceptible S. aureus, MSSA) in contrast to
the current low rate of methicillin-resistant S.
aureus (MRSA) colonisation in the UK.1
Carriage is genetically determined and repre-
sents a risk for infection, especially when
admitted to hospital for surgery. Endogenous
MSSA is a common cause of postoperative
infection.1 2 This risk is recognised by choice
of speciﬁc antistaphylococcal antibiotics for
surgical prophylaxis, especially high-risk pro-
cedures such as orthopaedic and vascular
implant surgeries.3 4
Concern over increasing MRSA led to the
introduction of a national MRSA screening
programme for all hospital admissions, in-
cluding elective surgical patients.5 The subse-
quent increase in screening swabs meant that
laboratories had to streamline their methods
and MRSA chromogenic agar was chosen to
aid rapid identiﬁcation.5 Unfortunately, this
agar cannot yield MSSA. Thus, a patient
might be deemed negative for MRSA car-
riage but could still be positive for MSSA. If
elective patients awaiting orthopaedic im-
plant surgery demonstrate MSSA carriage
Strengths and limitations of this study
▪ Simple adjustment of laboratory method allowed
detection of methicillin-susceptible Staphylococcus
aureus (MSSA) as well as methicillin-resistant
S. aureus.
▪ Decolonising MSSA-positive orthopaedic patients
before surgery protected them from deep MSSA
infection in bone and joints.
▪ The study highlights an important and costly
deficit in the current national screening tool for
high-risk surgery.
▪ Study limited due to one site setting in Scotland.
▪ Costs based on UK National Health Service
(NHS) practices only.
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then they are known to be at risk of postoperative MSSA
infection.2 3
Owing to ongoing sporadic MSSA infections among
orthopaedic patients, our health board approved the
decision to broaden preoperative screening to include
MSSA as well as MRSA for elective implant patients from
December 2013. Trauma patients receive immediate
care and proceed to surgery without prior screening.
This paper describes an audit of postoperative staphylo-
coccal infection among all elective and trauma ortho-
paedic patients at one hospital within two separate
6-month periods: January to June 2013 (period A:
MRSA screening only) and January to June 2014
(period B: screening for MSSA and MRSA). We
compare and contrast the MSSA infection rate between
all patients receiving orthopaedic surgery during both
study periods and present an evaluation of the change
to health service costs from a decision to adopt the
enhanced screening programme.
METHODS
The study hospital is a 550-bed acute district general
hospital with 24-hour accident and emergency (A&E)
department. The hospital offers a range of services
including management of elective and trauma patients
for orthopaedic surgery. Trauma patients are admitted
through A&E and receive immediate surgery if appropri-
ate. Elective patients attend the preassessment clinic for
evaluation of surgical ﬁtness, including MRSA screening
in accordance with national protocol.5 Orthopaedic ser-
vices are delivered by four consultants responsible for
>95% of all implant surgeries undertaken by the hos-
pital, which is the largest orthopaedic referral centre for
the health board. A number of severe MSSA implant
infections occurred in 2012, unrelated in time or space.
It was decided to pilot an enhanced screening pro-
gramme managed by preassessment for 3 months ( July
to September) in 2013 and audit the effect. Thus,
patients were swabbed as usual (nasal, perineal±wounds)
and request forms were tagged so that the laboratory
could distinguish specimens from orthopaedic patients
and process them for MSSA as well as MRSA. In the
event of cancellation of surgery, some patients were
recalled for repeat screening.
Laboratory methods
Swabs were transported to the laboratory and processed
on the day of collection. Standard operating protocol
was changed to encompass preliminary isolation of S.
aureus by switching from MRSA chromogenic to S. aureus
identiﬁcation (SAID) chromogenic agar. Characteristic
blue colonies were further tested for coagulase produc-
tion (Staphylase) and indeterminate reactions were con-
ﬁrmed with tube coagulase. Positive isolates were
characterised by automated technology (Vitek) includ-
ing antibiotic susceptibilities. The results were
authorised by the consultant microbiologist who
reported appropriate susceptibilities (ﬂucloxacillin; clar-
ythromycin; vancomycin; gentamicin and mupirocin).
Patient decolonisation
Authorised results were fed back to preassessment. A
standard letter detailing MSSA isolation and management
options was sent to the orthopaedic consultant responsible
for the patient. Conﬁrmed MSSA carriage at skin sites was
treated with 5 days Naseptin (chlorhexidine hydrochloride
0.1%; neomycin sulfate 0.5%) nasal cream applied three
times a day and daily chlorhexidine gluconate 4% body
washes. MRSA-positive patients received the same regimen
but with mupirocin 2% (Bactroban) nasal cream rather
than Naseptin. A known MSSA-positive patient would occa-
sionally present for surgery without having received any
clearance therapy; these patients were offered preopera-
tive Naseptin and a chlorhexidine shower. MRSA-positive
patients were deferred from surgery unless they had
received the appropriate decolonisation protocol. Surgical
prophylaxis for all orthopaedic patients was ﬂucloxacillin
±gentamicin or a glycopeptide, in accordance with local
prescribing policy.
Audit strategy
Following encouraging results from the 3-month pilot
study, additional MSSA screening for elective ortho-
paedic patients was implemented from mid-December
2013. We decided to conduct a formal audit of patient
outcome in order to evaluate the screening programme.
Two periods were chosen: the ﬁrst 6 months in 2013,
when only MRSA screening was performed, and the
same 6-month period in 2014, when both MSSA and
MRSA screenings were performed. These periods were
chosen to reﬂect seasonal variation, bypass the effect
from the 2013 pilot study and permit sufﬁcient
‘wash-out’ time between old and new screening policies.
We included orthopaedic trauma patients admitted
during the same periods as control because these
patients proceed to immediate surgery without screen-
ing. There were no policy changes in the management
of either trauma or elective orthopaedic patients during
the study period, including estates-related or infection
control programmes.
Data retrieval
The hospital database was searched for all orthopaedic
patients attending preassessment from 1 January to 1
July 2013 (period A) and for the same 6-month period
(period B) the following year, 2014. A separate search of
the microbiology database yielded every orthopaedic
patient submitting one or more samples requesting a
test for, or positive for, S. aureus from 1 January 2013
until 31 December 2014. Patients were then cross-
checked against microbiology and hospital records in
order to identify all elective and trauma patients present-
ing within the two periods; those screened for MRSA,
those screened for MSSA and MRSA, patients colonised
2 Dancer SJ, et al. BMJ Open 2016;6:e011642. doi:10.1136/bmjopen-2016-011642
Open Access
group.bmj.com on September 20, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
with MRSA or MSSA; and all patients identiﬁed with
postoperative staphylococcal infection within 1 month
after surgery (early-onset) or after 1 month following
surgery (late-onset). Patients were followed up for
1 year after surgery. New patients presenting outside
the two study periods were excluded. Postoperative
patients who missed prior screening and subsequently
developed infection were offered relevant screening.
The number of return trips to the operation theatre,
additional surgical interventions, intensive care unit
(ICU) admission, A&E and outpatient attendance,
microbiological investigations and length of stay (LOS)
were documented for all patients with postoperative
infection.
Cost data for screening activities and for laboratory and
clinical management of infection were obtained from a
number of resources, both local and national. Laboratory
consumables were recovered from manufacturers’ data at
nationally agreed National Health Service (NHS) cost;
biomedical scientist, hospital consultant, general practi-
tioner (GP) and nurse time costs were based on national
pay scales, with mid-point values selected for calculation.
Health board data were used to estimate the costs of
laboratory processing for individual tests, such as wound
swabs, blood cultures and aspirates, etc. These included
consumables, staff time, laboratory overheads (including
quality control, training and waste disposal) and speci-
men transport. The costs of all antimicrobial drugs and
other products were retrieved from the 2015 British
National Formulary (BNF) Online database at http://
www.bnf.org/products/bnf-online/. Clinical costs, such as
ICU, hospital bed-days, surgical procedures and out-
patient and A&E attendances were taken from NHS




Each patient with postoperative MSSA infection was
investigated to ascertain the severity of infection and
subsequent management.6 ‘Superﬁcial’ surgical site
infection was deﬁned as skin and soft tissue involvement
only; ‘deep’ infection (also organ/space infection) was
deﬁned as infected implant necessitating intravenous
antibiotics and further surgery. Patients with post-
operative staphylococcal infections unrelated to the sur-
gical site were not included.
Since it was not possible to calculate the total number
of trauma patients presenting at the A&E department
during the study periods, we selected all those who
received emergency surgery in trauma theatre. This pro-
vided the denominator for sepsis rates among trauma
patients during both study periods. We were able to
ascertain the total number of elective patients who
attended preassessment and this was used to calculate
the overall sepsis rates among elective orthopaedic
patients for both study periods.
Statistical analysis
CIs for the risk ratio were calculated using exact sample
methods. Wilson’s limit was used for the CIs for the pro-
portion. Tests of association were carried out using
Fisher’s exact test. The joint effects of elective compared
with trauma surgery and period were investigated
through a logistic regression using a log link. R V.3.2 was
used for the analysis, together with the epitools and
Hmisc libraries.
Cost modelling
The expected change to total health services costs were
modelled for a cohort of 500 elective orthopaedic
patients. The extra costs from additional MSSA screen-
ing were included as were the cost-savings from changes
to the number of cases of superﬁcial and deep infection.
All data uncertainties were included by ﬁtting prior stat-
istical distributions and running a probabilistic analysis
of 1000 simulations. Parameters that describe the costs
of additional MSSA screening (table 1) had uncertain-
ties represented by a 10% positive and negative variance.
Information on the resources used and subsequent treat-
ment costs (table 2; see online supplementary appendi-
ces 1–3) for cases of deep infection were used to update
a prior γ distribution to show the costs of treating a case
of deep infection. The cost of treating a superﬁcial
infection is shown in online supplementary appendix 4
and uncertainties were represented by a 10% positive
and negative variance. The relative risk of infection from
additional screening over baseline screening was esti-
mated from the data in table 3. Prior uncertainties
(online supplementary appendices 5 and 6) were speci-
ﬁed with a statistical distribution using calculated log
relative risk and SE. Applying the starting risk of infec-
tion shown in table 3 under conditions of baseline
screening provides estimates of the starting numbers of
infections among the cohort. These were modiﬁed by
the uncertain relative risks shown in online supplemen-
tary appendices 4 and 5 to predict the change in the
number of infections (see online supplementary appen-
dices 7 and 8). The expected cost of the enhanced
screening (see online supplementary appendix 9) and
the change in total costs was estimated.
RESULTS
During 1 January to 1 July 2013 (period A), 232 patients
underwent preoperative assessment before elective
orthopaedic surgery compared with 307 patients during
1 January to 1 July 2014 (period B; table 3). Over the
same two 6-month periods, 447 patients received emer-
gency orthopaedic surgery during period A compared
with 352 patients during period B. There were also an
unknown number of patients admitted directly from out-
patient clinics or transferred from other hospitals who
underwent orthopaedic surgery (table 3).
During period A, 2 (0.45%) and 10 (2.24%) of 447
trauma patients had superﬁcial MSSA and deep MSSA
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infections, respectively. These were similar to infection
rates for trauma patients during period B (superﬁcial: 4
of 352 (1.14%); deep: 5 of 352 (1.42%); p=1, Fisher’s
exact test; table 3). Of the 232 elective patients in period
A, 4 (1.72%) patients had superﬁcial MSSA and 15
(6.47%) had deep MSSA infections following implant
surgery; during period B, 6 (2%) of 307 elective patients
had superﬁcial MSSA infection with just 1 (0.3%) deep
infection (p=0.002; table 2 and 3). There is a signiﬁcant
interaction between trauma and elective surgery and
each period on the risk of MSSA infection (p=0.044).
Among trauma patients the risk ratio of any MSSA infec-
tion was 0.95 (95% CI 0.41 to 2.23) in period B com-
pared with period A, while the corresponding risk ratio
was 0.28 (95% CI 0.12 to 0.65) for elective patients. For
deep MSSA infections, the risk ratio was 0.58 (95% CI
0.20 to 1.67) for trauma patients and 0.05 (95% CI 0.01
to 0.36) for elective patients (p=0.011). Four additional
deep MSSA infections were identiﬁed during period B
in patients who had not attended preassessment or
received prior screening (table 3). They are not
included in the above analysis.




Swabs (nasal; perineal; ±wounds; urine) NAC
Patient counselling; swabbing; writing laboratory
form; tag patient notes
NAC
Laboratory process Transport and booking NAC
Urine microscopy; swabs plated out onto agar NAC
Identify and confirm colonies with Staphylase kit £103/kit, £0.035 per test
Purity plate (blood agar) BA plate: £0.18 test
VITEK ID and susceptibilities; reagents and
BMS time
Vitek Card £4.00, CLED purity plate £0.17,
consumables £0.30, 25 min BMS time £6.33
Reporting Microbiologist 1 hour (medic) £55, 5 min to authorise
Preassessment action (staff time) 1 hour (band 5 nurse): £12.50, 10 min per patient
Topical clearance Consultant alert and action 1 hour (medic) £55, 5 min
Secretarial GP letter 1 hour (secretary) £9.00, 5 min
GP action 1 hour (salaried GP): £35, 10 min
Naseptin (5 days) £2.45 per tube
Chlorhexidine gluconate 4% bath (5 days)* £5.25 per 500 mL
*Not all patients received the full 5 day course of chlorhexidine washes.
GP, general practitioner; NAC, no additional cost.
Table 2 Outcome of 16 postoperative deep MSSA infections among elective orthopaedic surgery patients during two
6-month periods (2013–2014)
Year Site Management Other LOS OPD
2013 Hip Failed DAIR → 1-stage ICU 3d 53 4
2013 Knee DAIR → revision TKR – 19 0
2013 Ankle Failed DAIR ×2 → failed 2-stage → fusion Osteomyelitis 313 8
2013 Tibia Failed DAIR ×2 → metal removed A&E 7 9
2013 Ankle Failed DAIR ×3 → failed 2-stage Osteomyelitis 30 19
2013 Hip Failed DAIR ×2 → revision ICU 6d; positive BLC 40 12
2013 Hip Failed DAIR A&E; ICU 5d; positive BLC 16 1
2013 Knee Failed DAIR → revision A&E 40 7
2013 Tibia Failed DAIR → metal removed – 12 5
2013 Knee Revision TKR – 4 5
2013 Hip Revision THR A&E ×3; C.diff; ICU 2D 49 0
2013 Ankle DAIR A&E 6 1
2013 Toe Failed DAIR ×2 → A&E 11 10
2013 Knee Failed DAIR – 4 3
2013 Ankle DAIR → metal removed ICU 8d 8 4
2014 Ankle DAIR Positive BLC 26 1
A&E, accident and emergency; BLC, blood cultures; C. diff, Clostridium difficile; DAIR, debridement-antibiotics-implant retention; ICU,
intensive care unit; LOS, length of stay; MSSA, methicillin-susceptible Staphylococcus aureus; OPD, outpatient department; THR, total hip
revision; TKR, total knee revision.
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Of the 307 patients screened by preassessment in
period B, 89 (29%, 95% CI 24% to 34%) were identiﬁed
as carriers. This supports the premise that around
one-third of people are colonised with coagulase-positive
staphylococci.1 There was only 1 (0.3%) deep MSSA
infection among the 307 screened elective patients,
whereas there were 30 (2.9%) deep MSSA infections
among all the unscreened patients (n=1031), whether
managed as elective or trauma (table 3). Formal com-
parison of patient cohorts is not considered further
because we did not adjust for operation type, age or
length of operation, all of which differ between trauma
and elective patients. Although the numbers are small,
elective patients were 2.89 times (95% CI 1.32
to 6.33; p=0.009) more likely than trauma patients in
period A to suffer deep MSSA infection (elective 6.47%
vs trauma 2.24%).
Patients with conﬁrmed postoperative MSSA infection
(superﬁcial and deep) who missed prior MSSA screen-
ing were investigated further. Of the 44 patients with
MSSA infection, 17 were screened and 14 of these
demonstrated nasal MSSA (table 3). These
ﬁgures include four elective patients admitted during
period B who did not attend preassessment. There were
three patients deemed negative following prior screen-
ing who suffered postoperative MSSA infection. Repeat
nasal screening after conﬁrmation of postoperative
MSSA infection then established presence of MSSA.
Before and throughout the entire study period,
patients were screened for MRSA in accordance with
national guidelines.5 This occurred for elective patients
before surgery but trauma patients usually received
surgery before the screening took place. The number of
MRSA infections among orthopaedic patients was negli-
gible for both periods (A: one patient; B: no MRSA
infections), although superﬁcial carriage was occasion-
ally identiﬁed. There were no patients with both MSSA
and MRSA at the same time. Given that there were so
few MRSA infections, these patients are not considered
further.
Table 4 Statistical summary of relative risks, screening costs, infections prevented and potential cost-savings
Minimum Maximum Median Mean
Relative risk superficial 0.14 10.10 1.21 1.48
Relative risk deep 0.00 2.34 0.05 0.09
Costs of screening £17 069 £19 356 £18 284 £18 269
Superficial infections prevented* −78.46 7.42 −1.84 −4.13
Deep infections prevented* −43.42 32.22 30.67 29.37
Potential cost-savings from superficial infections prevented† −£9957 £943 −£231 −£524
Potential cost-savings from deep infections prevented† −£3 473 254 £3 360 145 £830 758 £833 334
Change to total costs† −£3 342 107 £3 491 865 −£812 559 −£814 541
*Positive numbers mean cases are prevented.
†Negative numbers mean costs are saved.
Table 3 MSSA infection outcome of all orthopaedic patients during two 6-month periods
Period A
January to June 2013
No MSSA screen
Period B
January to June 2014
MSSA screen (elective patients only)
Trauma Elective Trauma Elective NK*
Total: 447 Total: 232 Total: 352 Total: 307 Total: NK






No MSSA infection† 435 (97.31%) 213 (91.81%) 343 (97.44%) 215 (97.7%) 85 NK
Superficial MSSA infection‡ 2 (0.45%) 4 (1.72%) 4 (1.14%) 2 (0.7%) 4 (1.3%) 0 (0%)
(postoperative MSSA carriage) (0) (1) (1) (1§) (4¶) (0)
Deep MSSA infection** 10 (2.24%) 15 (6.47%) 5 (1.42%) 1†† (0.3%) 0 (0%) 4 NK%
(postoperative MSSA carriage) (1) (7§) (2) (0) (2)
Among elective patients the risk ratio of any MSSA infection was 0.28 (95% CI 0.12 to 0.65) in period B compared with period A; risk ratio of
any MSSA infection was 0.95 (95% CI 0.41 to 2.23) in period B compared with period A.
*Unscreened patients admitted for surgery from outpatients or another hospital.
†Excluding patients presenting at another hospital.
‡Superficial infection: skin and soft tissue only.
§Original screen negative (one patient); positive for MSSA postsurgery.
¶All four patients had superficial MSSA infection with strains resembling nasal isolates.
**Deep infection: intravenous antibiotics+further surgery.
††Patient screened twice for MSSA but no evidence of carriage.
MSSA, methicillin-susceptible Staphylococcus aureus; Neg, negative; NK, not known; Pos, positive.
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Cost modelling
We estimate that enhanced screening costs £18 269 for
500 patients screened (table 4). There would be an add-
itional 3.04 superﬁcial infections arising but 29.12 fewer
deep infections. The overall change in costs would be
savings of £831 678; this is caused by the high costs of
treating a deep infection that are avoided due to
enhanced screening (see online supplementary appen-
dix 3). The uncertainty in the estimated change in total
cost is shown in ﬁgure 1. Interpreting this plot for
decision-making suggests there is an 86.8% chance that
implementing enhanced screening is cost-saving. A
rational and risk neutral decision maker should adopt
enhanced screening, and on average this will yield a
saving of £831 678 per 500 patients screened.
DISCUSSION
Given the focus on MRSA, it is not surprising that MSSA
infections have continued unabated in UK hospitals.
While the rate of MRSA bacteraemia has been decreas-
ing since 2008, the MSSA bacteraemia rate has contin-
ued with little change.7 8 This study investigated patients
receiving orthopaedic implant surgery, and found that
MSSA carriage remains an important risk factor for post-
operative infection, whether admitted for trauma or as a
planned elective.
Most of the infections identiﬁed during the period
without MSSA screening were classiﬁed as ‘deep’, which
mandated the need for further surgery. Previous reports
state that the average cost of a failed implant varies from
£7000 to £36 000 depending on the site, debridement,
antibiotics and/or revision surgery.9 10 These ﬁgures do
not necessarily include extra LOS. We found that the
average total cost of managing a deep MSSA implant
infection occurring in period A was about £55 500,
which exceeds the ﬁgures quoted. Since we included
parameters such as LOS, intensive care days, microbio-
logical tests, A&E and outpatient attendance, it is pos-
sible that our ﬁgures are a more realistic illustration of
additional costs due to postoperative orthopaedic infec-
tion. A recent paper from a London teaching hospital
(with a domiciliary antibiotic facility) found that the
average LOS for 45 patients needing total knee arthro-
plasty was 21.49 days.10 Our 16 patients had an average
LOS of 40 days (table 2), although if one single patient
who stayed in hospital for 313 days is removed, 15
patients had an average LOS of 21.3 days, which is
similar to the London hospital data.
There are caveats to our ﬁndings when balancing cost-
savings from fewer failed implants against the screening
costs (table 1). Broadening laboratory protocols to
include MSSA identiﬁcation were cost neutral due to the
use of less expensive agar, but there were additional
administrative and managerial costs for preassessment,
orthopaedic secretaries and clinicians. Most of the
product costs were absorbed by the hospital (nasal
creams and antiseptic washes) but some patients
obtained a prescription from their GP. Furthermore,
some operations were postponed, in which case the
patients concerned were asked to attend preassessment
for repeat screening. Given this, it is possible that the
overall cost of the screening programme (∼£18 000)
may have been underestimated. The savings made from
reduced numbers of deep orthopaedic infections were
substantial, however, and it is assumed that they more
than covered the costs of the screening initiative.11 12
The study has some strengths and limitations. Simple
adjustment of laboratory method allowed detection of
MSSA as well as MRSA without compromising laboratory
staff or usual practices. The amendment to standard
operating procedure was cost neutral. Decolonising
MSSA-positive orthopaedic patients before surgery
appeared to protect them from deep MSSA infection in
bone and joints, although we accept the causal nature of
the association. The study highlights an important and
costly deﬁcit in the current national staphylococcal
screening tool for high-risk surgery. The ﬁndings are
limited due to the single site setting in a relatively
deprived area of Scotland, however, and the fact that
costs are based on UK NHS practices only. This means
that the reported outcome may not apply to other ortho-
paedic units, although they may be relevant during an
‘outbreak’ situation.
MSSA isolates were not retained for further molecular
characterisation so we could not demonstrate identity
between colonising and infecting strains in the same
patient. This was due in part to the retrospective audit for
period A. There have been many previous studies demon-
strating genotypic links between colonising strains and
postsurgical infection due to the carrier strain.1 11 We had
no wish to duplicate this work. However, we did notice
indistinguishable antibiograms between MSSA isolates
recovered from screening swabs and those submitted days
Figure 1 Figure showing uncertainty in estimated change to
total cost with enhanced screening of elective orthopaedic
patients awaiting implant surgery. The area to the left of the
dashed line is 86.8% of the distribution. This means that there
is an 86.8% chance that implementing enhanced screening is
cost-saving (see text).
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or weeks later from samples taken to conﬁrm post-
operative infection. Occasionally, there were multiple
samples from the same patient, including blood cultures,
aspirate and tissues, taken before or during revision
surgery that generated unique antimicrobial susceptibility
patterns, including minimal inhibitory concentration
(MIC) values, to key antibiotics. We believe that patients
habitually colonised with their own unique strain are at
risk from infection due to their carried strain when com-
promised by a major surgical intervention.1–3 Three
patients, originally negative for MSSA carriage, were
found to be positive following conﬁrmation of post-
operative MSSA infection. They may illustrate transient
staphylococcal carriage, which also poses an infection risk
for surgical patients.1 An alternative explanation is that ori-
ginal screening swabs did not detect a colonising strain; or
it failed to grow, or was overlooked by the laboratory. PCR
might ameliorate some false-negative results, but this
method requires costly consumables and delivers
increased numbers of false positives.13
MRSA bacteraemia rates have fallen across the UK
over the past 10 years.7 This fall may be attributable to
the universal MRSA screening programme, which
recommends the use of MRSA chromogenic agar.14
Selective agar facilitates the identiﬁcation of MRSA but
inhibits the growth of MSSA. This might explain why
MRSA bacteraemia rates have reduced in the UK,
whereas MSSA rates have not. These trends contrast with
those in Australia, where MRSA chromogenic agar is not
universally employed and both MRSA and MSSA rates
have decreased in parallel over the same time period.15
In conclusion, broadening the national screening
policy to include MSSA for elective orthopaedic surgery
patients awaiting implant procedures identiﬁed pre-
operative carriage in nearly one-third of the patients.
The screening programme may have facilitated a reduc-
tion in deep postoperative infection in the screened
patient cohort. The cost-beneﬁts from enhanced screen-
ing in this high-risk population of surgical patients are
substantial.12
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